Target intelligence / Profile preview

DNA purine N7 sites

Molecular classification
Other
01

Overview

DNA purine N7 sites refer to the nitrogen atom at position 7 of the purine ring in guanine and adenine bases within the major groove of double-stranded DNA. This site is highly nucleophilic and sterically accessible, making it the primary target for many classical chemotherapeutic agents, including platinum-based drugs (such as cisplatin, carboplatin, and oxaliplatin) and alkylating agents (such as nitrogen mustards, cyclophosphamide, and temozolomide). Covalent modification or coordination at the N7 position of purines disrupts the DNA double helix structure, forming monoadducts, intrastrand crosslinks, and interstrand crosslinks. These lesions physically block DNA replication and transcription machinery, leading to replication fork collapse, double-strand breaks, and the activation of DNA damage response pathways. Ultimately, the accumulation of unrepaired DNA damage triggers apoptosis, particularly in rapidly proliferating cancer cells. However, because these agents lack specificity for cancer cells, targeting DNA purine N7 sites is associated with significant toxicities, including myelosuppression, nephrotoxicity, and the risk of secondary malignancies due to mutagenic effects in healthy tissues.

Other names
DNA purine N7 positionDNA purine N7 atomsGuanine N7 positionAdenine N7 positionN7 of guanineN7 of adeninePurine N7 of DNADNA guanine N7DNA adenine N7
02

Mechanism of action

Covalent binding or coordination to the nucleophilic N7 position of purine bases (primarily guanine) in DNA, leading to the formation of DNA adducts, intrastrand crosslinks, and interstrand crosslinks. This blocks DNA replication and transcription, triggers the DNA damage response, and induces apoptosis.

03

Biological functions

Cell cycleApoptosisCell deathOther
04

Disease associations

CancerOther
05

Safety considerations

MyelosuppressionNephrotoxicityOtotoxicitySecondary malignanciesHemorrhagic cystitisInfertilityTeratogenicity
06

Interacting drugs

13 more in the full profile.

07

Biomarkers

MGMT promoter methylationBRCA1 mutation statusBRCA2 mutation statusERCC1 expressionMismatch repair (MMR) statusN7-alkylguanine adduct levels

Beyond the preview

Go deeper on DNA purine N7 sites.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA purine N7 sites.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call